In the VIKTORY study, GC patients with MET amplification had high response rates (10/20, ORR 50%; 95% CI 28.0–71.9) to savolitinib monotherapy, and 70% of the responders had an enhanced MET copy number (>10 copies) [30]. Here, MET is linked to gastric cancer.